 | • レポートコード：MRC2Q12-16818 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、有痛糖尿病性神経障害治療薬のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 有痛糖尿病性神経障害治療薬のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 有痛糖尿病性神経障害治療薬の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 有痛糖尿病性神経障害治療薬のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの有痛糖尿病性神経障害治療薬の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の有痛糖尿病性神経障害治療薬の売上および2028年までの予測に焦点を当てています。 有痛糖尿病性神経障害治療薬のグローバル主要企業には、Daiichi Sankyo Company, Limited、Eli Lilly and Company、Johnson & Johnson Services, Inc、Novartis AG、Pfizer Inc.、Grunenthal GmbH、ViroMed Co.、Collegium Pharmaceutical, Inc、Acorda Therapeutics, Inc、Zydus Pharmaceuticals、Mallinckrodt, Inc、Macleods Pharmaceuticals Ltd.、Lupin Pharmaceuticalsなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 有痛糖尿病性神経障害治療薬市場は、タイプとアプリケーションによって区分されます。世界の有痛糖尿病性神経障害治療薬市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 経口、注射、その他 【アプリケーション別セグメント】 病院、クリニック、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 有痛糖尿病性神経障害治療薬製品概要 - タイプ別市場（経口、注射、その他） - アプリケーション別市場（病院、クリニック、その他） - 調査の目的 ・エグゼクティブサマリー - 世界の有痛糖尿病性神経障害治療薬販売量予測2017-2028 - 世界の有痛糖尿病性神経障害治療薬売上予測2017-2028 - 有痛糖尿病性神経障害治療薬の地域別販売量 - 有痛糖尿病性神経障害治療薬の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別有痛糖尿病性神経障害治療薬販売量 - 主要メーカー別有痛糖尿病性神経障害治療薬売上 - 主要メーカー別有痛糖尿病性神経障害治療薬価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（経口、注射、その他） - 有痛糖尿病性神経障害治療薬のタイプ別販売量 - 有痛糖尿病性神経障害治療薬のタイプ別売上 - 有痛糖尿病性神経障害治療薬のタイプ別価格 ・アプリケーション別市場規模（病院、クリニック、その他） - 有痛糖尿病性神経障害治療薬のアプリケーション別販売量 - 有痛糖尿病性神経障害治療薬のアプリケーション別売上 - 有痛糖尿病性神経障害治療薬のアプリケーション別価格 ・北米市場 - 北米の有痛糖尿病性神経障害治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の有痛糖尿病性神経障害治療薬市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの有痛糖尿病性神経障害治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の有痛糖尿病性神経障害治療薬市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の有痛糖尿病性神経障害治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の有痛糖尿病性神経障害治療薬市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の有痛糖尿病性神経障害治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の有痛糖尿病性神経障害治療薬市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの有痛糖尿病性神経障害治療薬市場規模（タイプ別、アプリケーション別） - 主要国別の有痛糖尿病性神経障害治療薬市場規模（トルコ、サウジアラビア） ・企業情報 Daiichi Sankyo Company, Limited、Eli Lilly and Company、Johnson & Johnson Services, Inc、Novartis AG、Pfizer Inc.、Grunenthal GmbH、ViroMed Co.、Collegium Pharmaceutical, Inc、Acorda Therapeutics, Inc、Zydus Pharmaceuticals、Mallinckrodt, Inc、Macleods Pharmaceuticals Ltd.、Lupin Pharmaceuticals ・産業チェーン及び販売チャネル分析 - 有痛糖尿病性神経障害治療薬の産業チェーン分析 - 有痛糖尿病性神経障害治療薬の原材料 - 有痛糖尿病性神経障害治療薬の生産プロセス - 有痛糖尿病性神経障害治療薬の販売及びマーケティング - 有痛糖尿病性神経障害治療薬の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 有痛糖尿病性神経障害治療薬の産業動向 - 有痛糖尿病性神経障害治療薬のマーケットドライバー - 有痛糖尿病性神経障害治療薬の課題 - 有痛糖尿病性神経障害治療薬の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Painful Diabetic Neuropathy Drug estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Painful Diabetic Neuropathy Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Painful Diabetic Neuropathy Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Painful Diabetic Neuropathy Drug is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Painful Diabetic Neuropathy Drug include Daiichi Sankyo Company, Limited, Eli Lilly and Company, Johnson & Johnson Services, Inc, Novartis AG, Pfizer Inc., Grunenthal GmbH, ViroMed Co., Collegium Pharmaceutical, Inc and Acorda Therapeutics, Inc, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Painful Diabetic Neuropathy Drug companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Painful Diabetic Neuropathy Drug market. Further, it explains the major drivers and regional dynamics of the global Painful Diabetic Neuropathy Drug market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Daiichi Sankyo Company, Limited
Eli Lilly and Company
Johnson & Johnson Services, Inc
Novartis AG
Pfizer Inc.
Grunenthal GmbH
ViroMed Co.
Collegium Pharmaceutical, Inc
Acorda Therapeutics, Inc
Zydus Pharmaceuticals
Mallinckrodt, Inc
Macleods Pharmaceuticals Ltd.
Lupin Pharmaceuticals
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Painful Diabetic Neuropathy Drug Segment by Type
Oral
Injection
Others
Painful Diabetic Neuropathy Drug Segment by Application
Hospital
Clinic
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Painful Diabetic Neuropathy Drug market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Painful Diabetic Neuropathy Drug market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Painful Diabetic Neuropathy Drug, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Painful Diabetic Neuropathy Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Painful Diabetic Neuropathy Drug revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Painful Diabetic Neuropathy Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Painful Diabetic Neuropathy Drug revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Daiichi Sankyo Company, Limited, Eli Lilly and Company, Johnson & Johnson Services, Inc, Novartis AG, Pfizer Inc., Grunenthal GmbH, ViroMed Co., Collegium Pharmaceutical, Inc and Acorda Therapeutics, Inc, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Painful Diabetic Neuropathy Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Painful Diabetic Neuropathy Drug companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Painful Diabetic Neuropathy Drug revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Painful Diabetic Neuropathy Drug Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Oral
1.2.3 Injection
1.2.4 Others
1.3 Market by Application
1.3.1 Global Painful Diabetic Neuropathy Drug Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Painful Diabetic Neuropathy Drug Market Perspective (2017-2028)
2.2 Painful Diabetic Neuropathy Drug Growth Trends by Region
2.2.1 Painful Diabetic Neuropathy Drug Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Painful Diabetic Neuropathy Drug Historic Market Size by Region (2017-2022)
2.2.3 Painful Diabetic Neuropathy Drug Forecasted Market Size by Region (2023-2028)
2.3 Painful Diabetic Neuropathy Drug Market Dynamics
2.3.1 Painful Diabetic Neuropathy Drug Industry Trends
2.3.2 Painful Diabetic Neuropathy Drug Market Drivers
2.3.3 Painful Diabetic Neuropathy Drug Market Challenges
2.3.4 Painful Diabetic Neuropathy Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Painful Diabetic Neuropathy Drug Players by Revenue
3.1.1 Global Top Painful Diabetic Neuropathy Drug Players by Revenue (2017-2022)
3.1.2 Global Painful Diabetic Neuropathy Drug Revenue Market Share by Players (2017-2022)
3.2 Global Painful Diabetic Neuropathy Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Painful Diabetic Neuropathy Drug Revenue
3.4 Global Painful Diabetic Neuropathy Drug Market Concentration Ratio
3.4.1 Global Painful Diabetic Neuropathy Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Painful Diabetic Neuropathy Drug Revenue in 2021
3.5 Painful Diabetic Neuropathy Drug Key Players Head office and Area Served
3.6 Key Players Painful Diabetic Neuropathy Drug Product Solution and Service
3.7 Date of Enter into Painful Diabetic Neuropathy Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Painful Diabetic Neuropathy Drug Breakdown Data by Type
4.1 Global Painful Diabetic Neuropathy Drug Historic Market Size by Type (2017-2022)
4.2 Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Type (2023-2028)
5 Painful Diabetic Neuropathy Drug Breakdown Data by Application
5.1 Global Painful Diabetic Neuropathy Drug Historic Market Size by Application (2017-2022)
5.2 Global Painful Diabetic Neuropathy Drug Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Painful Diabetic Neuropathy Drug Market Size (2017-2028)
6.2 North America Painful Diabetic Neuropathy Drug Market Size by Type
6.2.1 North America Painful Diabetic Neuropathy Drug Market Size by Type (2017-2022)
6.2.2 North America Painful Diabetic Neuropathy Drug Market Size by Type (2023-2028)
6.2.3 North America Painful Diabetic Neuropathy Drug Market Share by Type (2017-2028)
6.3 North America Painful Diabetic Neuropathy Drug Market Size by Application
6.3.1 North America Painful Diabetic Neuropathy Drug Market Size by Application (2017-2022)
6.3.2 North America Painful Diabetic Neuropathy Drug Market Size by Application (2023-2028)
6.3.3 North America Painful Diabetic Neuropathy Drug Market Share by Application (2017-2028)
6.4 North America Painful Diabetic Neuropathy Drug Market Size by Country
6.4.1 North America Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022)
6.4.2 North America Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Painful Diabetic Neuropathy Drug Market Size (2017-2028)
7.2 Europe Painful Diabetic Neuropathy Drug Market Size by Type
7.2.1 Europe Painful Diabetic Neuropathy Drug Market Size by Type (2017-2022)
7.2.2 Europe Painful Diabetic Neuropathy Drug Market Size by Type (2023-2028)
7.2.3 Europe Painful Diabetic Neuropathy Drug Market Share by Type (2017-2028)
7.3 Europe Painful Diabetic Neuropathy Drug Market Size by Application
7.3.1 Europe Painful Diabetic Neuropathy Drug Market Size by Application (2017-2022)
7.3.2 Europe Painful Diabetic Neuropathy Drug Market Size by Application (2023-2028)
7.3.3 Europe Painful Diabetic Neuropathy Drug Market Share by Application (2017-2028)
7.4 Europe Painful Diabetic Neuropathy Drug Market Size by Country
7.4.1 Europe Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022)
7.4.2 Europe Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size (2017-2028)
8.2 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Type
8.2.1 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Painful Diabetic Neuropathy Drug Market Share by Type (2017-2028)
8.3 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Application
8.3.1 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Painful Diabetic Neuropathy Drug Market Share by Application (2017-2028)
8.4 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region
8.4.1 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Painful Diabetic Neuropathy Drug Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Painful Diabetic Neuropathy Drug Market Size (2017-2028)
9.2 Latin America Painful Diabetic Neuropathy Drug Market Size by Type
9.2.1 Latin America Painful Diabetic Neuropathy Drug Market Size by Type (2017-2022)
9.2.2 Latin America Painful Diabetic Neuropathy Drug Market Size by Type (2023-2028)
9.2.3 Latin America Painful Diabetic Neuropathy Drug Market Share by Type (2017-2028)
9.3 Latin America Painful Diabetic Neuropathy Drug Market Size by Application
9.3.1 Latin America Painful Diabetic Neuropathy Drug Market Size by Application (2017-2022)
9.3.2 Latin America Painful Diabetic Neuropathy Drug Market Size by Application (2023-2028)
9.3.3 Latin America Painful Diabetic Neuropathy Drug Market Share by Application (2017-2028)
9.4 Latin America Painful Diabetic Neuropathy Drug Market Size by Country
9.4.1 Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022)
9.4.2 Latin America Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size (2017-2028)
10.2 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Type
10.2.1 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Painful Diabetic Neuropathy Drug Market Share by Type (2017-2028)
10.3 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Application
10.3.1 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Painful Diabetic Neuropathy Drug Market Share by Application (2017-2028)
10.4 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country
10.4.1 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Painful Diabetic Neuropathy Drug Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Daiichi Sankyo Company, Limited
11.1.1 Daiichi Sankyo Company, Limited Company Details
11.1.2 Daiichi Sankyo Company, Limited Business Overview
11.1.3 Daiichi Sankyo Company, Limited Painful Diabetic Neuropathy Drug Introduction
11.1.4 Daiichi Sankyo Company, Limited Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.1.5 Daiichi Sankyo Company, Limited Recent Developments
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Painful Diabetic Neuropathy Drug Introduction
11.2.4 Eli Lilly and Company Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.2.5 Eli Lilly and Company Recent Developments
11.3 Johnson & Johnson Services, Inc
11.3.1 Johnson & Johnson Services, Inc Company Details
11.3.2 Johnson & Johnson Services, Inc Business Overview
11.3.3 Johnson & Johnson Services, Inc Painful Diabetic Neuropathy Drug Introduction
11.3.4 Johnson & Johnson Services, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.3.5 Johnson & Johnson Services, Inc Recent Developments
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Painful Diabetic Neuropathy Drug Introduction
11.4.4 Novartis AG Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.4.5 Novartis AG Recent Developments
11.5 Pfizer Inc.
11.5.1 Pfizer Inc. Company Details
11.5.2 Pfizer Inc. Business Overview
11.5.3 Pfizer Inc. Painful Diabetic Neuropathy Drug Introduction
11.5.4 Pfizer Inc. Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.5.5 Pfizer Inc. Recent Developments
11.6 Grunenthal GmbH
11.6.1 Grunenthal GmbH Company Details
11.6.2 Grunenthal GmbH Business Overview
11.6.3 Grunenthal GmbH Painful Diabetic Neuropathy Drug Introduction
11.6.4 Grunenthal GmbH Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.6.5 Grunenthal GmbH Recent Developments
11.7 ViroMed Co.
11.7.1 ViroMed Co. Company Details
11.7.2 ViroMed Co. Business Overview
11.7.3 ViroMed Co. Painful Diabetic Neuropathy Drug Introduction
11.7.4 ViroMed Co. Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.7.5 ViroMed Co. Recent Developments
11.8 Collegium Pharmaceutical, Inc
11.8.1 Collegium Pharmaceutical, Inc Company Details
11.8.2 Collegium Pharmaceutical, Inc Business Overview
11.8.3 Collegium Pharmaceutical, Inc Painful Diabetic Neuropathy Drug Introduction
11.8.4 Collegium Pharmaceutical, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.8.5 Collegium Pharmaceutical, Inc Recent Developments
11.9 Acorda Therapeutics, Inc
11.9.1 Acorda Therapeutics, Inc Company Details
11.9.2 Acorda Therapeutics, Inc Business Overview
11.9.3 Acorda Therapeutics, Inc Painful Diabetic Neuropathy Drug Introduction
11.9.4 Acorda Therapeutics, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.9.5 Acorda Therapeutics, Inc Recent Developments
11.10 Zydus Pharmaceuticals
11.10.1 Zydus Pharmaceuticals Company Details
11.10.2 Zydus Pharmaceuticals Business Overview
11.10.3 Zydus Pharmaceuticals Painful Diabetic Neuropathy Drug Introduction
11.10.4 Zydus Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.10.5 Zydus Pharmaceuticals Recent Developments
11.11 Mallinckrodt, Inc
11.11.1 Mallinckrodt, Inc Company Details
11.11.2 Mallinckrodt, Inc Business Overview
11.11.3 Mallinckrodt, Inc Painful Diabetic Neuropathy Drug Introduction
11.11.4 Mallinckrodt, Inc Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.11.5 Mallinckrodt, Inc Recent Developments
11.12 Macleods Pharmaceuticals Ltd.
11.12.1 Macleods Pharmaceuticals Ltd. Company Details
11.12.2 Macleods Pharmaceuticals Ltd. Business Overview
11.12.3 Macleods Pharmaceuticals Ltd. Painful Diabetic Neuropathy Drug Introduction
11.12.4 Macleods Pharmaceuticals Ltd. Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.12.5 Macleods Pharmaceuticals Ltd. Recent Developments
11.13 Lupin Pharmaceuticals
11.13.1 Lupin Pharmaceuticals Company Details
11.13.2 Lupin Pharmaceuticals Business Overview
11.13.3 Lupin Pharmaceuticals Painful Diabetic Neuropathy Drug Introduction
11.13.4 Lupin Pharmaceuticals Revenue in Painful Diabetic Neuropathy Drug Business (2017-2022)
11.13.5 Lupin Pharmaceuticals Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer